Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial

Alan K. Burnett(Cardiff University), Keith Wheatley(Cancer Research UK Clinical Trials Unit), Robert K. Hills(Cancer Research UK Clinical Trials Unit), Andrew Duncombe(University of Birmingham), Anthony H. Goldstone(Royal London Hospital), Brenda Gibson(Royal Hospital for Children), Mary‐Frances McMullin(University of Birmingham), Donald Milligan(National Health Service), A. G. Prentice(University of Birmingham)

Journal of Clinical Oncology

December 29, 2009

10.1200/jco.2009.22.9088

Cited by 229

Related Papers

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

|Blood|2009|3.4k

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

|Blood|2010|1.9k

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

|Blood|2018|1k

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

|Blood|2008|957

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

|Blood|2006|843